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Background
Antiplatelet therapy (APT) is known to substantially
reduce mortality and rate of ischaemic complications
after coronary artery bypass grafting (CABG). Rate of
perioperative APT resistance varies widely and could be
influenced by cardiopulmonary bypass (CPB). The pur-
pose of the study was perioperative assessment of plate-
let function with respect to administered APT and CPB,
and determination of patients with APT resistance who
could benefit from more aggresive treatment strategy.
Methods
In prospective study we enrolled 192 patients under-
going elective CABG. Patients were divided into 4
groups with respect to their preoperative APT manage-
ment. All patients received Aspirin (ASA) 300 mg/ day
postoperatively starting on the day of procedure. Platelet
function was assessed prior to surgery and at fourth
postoperative day (POD 4) using multiple electrode
aggregometry (MEA). Adenosine diphosphate (ADP
test) and arachidonic acid (ASPI test) induced platelet
aggregation tests were used.
Results
Group of patients exposed to ASA preoperatively had
lower values of ASPI test (P<0.001) comparing to
patients not receiving ASA. However, we registered
28.6% ASA resistant patients. Both ASPI (P<0.001) and
ADP (P<0.001) test values increased significantly at
POD 4, suggesting postoperative platelet hyperactivity.
Postoperatively, we registered 33.3% ASA resistant
patients despite higher ASA dosing regimen.
Conclusion
MEA can recognize patients with ASA resistance during
the both the pre- and post- CABG period. Postopera-
tively, ASA 300mg did not sufficiently inhibit platelet
aggregation in 33.3% patients. In this subgroup, dual
antiplatelet therapy with ASA and clopidogrel could be
useful for maintaining graft patency, and preventing
adverse ischemic events.
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